Interbiome

Executive Summary

Interbiome, founded in 2019 and headquartered in Boston, is a Contract Manufacturing Organization (CMO) specializing in microbiome-based therapeutics. The company provides essential manufacturing services to biotech teams preparing drug candidates for clinical trials, particularly targeting gastrointestinal and metabolic disorders. Interbiome's core mission is to transform bio-manufacturing for next-generation microbiome therapies, addressing a critical bottleneck in the development pipeline. By offering scalable, high-quality production capabilities, the company enables its clients to advance their discoveries from lab to clinic efficiently. Despite operating in a niche but rapidly growing sector, Interbiome remains a relatively young private entity with limited public financial disclosures. Its success hinges on securing partnerships with emerging microbiome drug developers and successfully scaling its manufacturing processes to meet regulatory standards. As the microbiome therapeutic field gains momentum, Interbiome is well-positioned to capitalize on the increasing demand for specialized CMO services, though competition from larger contract manufacturing organizations poses a challenge. The company's potential is tied to its ability to establish a strong track record of client successes and expand its operational capacity.

Upcoming Catalysts (preview)

• Q2 2026Announcement of New Client Partnership with a Late-Stage Microbiome Biotech70% success
• Q4 2026Expansion of Manufacturing Capacity or New Facility60% success
• Q3 2026Client's Drug Candidate Achieves Positive Phase 2/3 Results50% success